Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nifurtoinol is a nitrofuran-derivative antibiotic used primarily for the treatment of urinary tract infections. It is bactericidal against most gram-positive and gram-negative urinary tract pathogens. As a member of the nitrofuran class, it acts as an antiinfective agent and antibacterial drug. Its mechanism involves bacterial enzyme-mediated reduction of its nitro group, leading to the formation of reactive intermediates that damage bacterial DNA and other macromolecules. Nifurtoinol is administered orally and is excreted renally, with 40–50% eliminated within the first 12 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nifurtoinol.